Anticancer activity of novel unnatural synthetic isoprenoids
Val R Adams1, David L Deremer, Bojana Stevich
1Department of Pharmacy Practice and Science, University of Kentucky, Lexington, KY 40536, USA. vadam0@email.uky.edu
Background:
The KRAS oncogene has a high prevalence in solid malignancies. Targeting KRAS and inappropriate activation of the MAPK pathway with novel drugs is of interest. This study developed and screened a library of compounds designed to inhibit KRAS signaling by altering prenyl function.
Materials And Methods:
To screen a library of novel farnesyl analogs for their anticancer activity in human lung cancer and breast cancer cell lines. To evaluate if the designed and actual pharmacology are congruent.
Results:
Sixty-seven novel compounds were tested and 70% of them screened positive for activity in at least one cell line. Two active compounds inhibited phosphorylation of MAP kinase consistent with KRAS inhibition.
Conclusion:
Although 47 of the 67 novel agents screened positive for activity, none of them were highly potent. However, targeting RAS with compounds that compete with farnesyl and geranylgeranyl modification of the protein remains viable and further work is already underway to create second generation molecules.
Insights
Researchers developed novel compounds targeting KRAS signaling by altering prenyl function for cancer treatment. While not highly potent, the strategy shows promise for developing future anti-RAS therapies.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- The KRAS oncogene is frequently implicated in various solid tumors.
- Dysregulated MAPK pathway activation, often downstream of KRAS, is a key driver in cancer progression.
- Targeting KRAS signaling represents a significant therapeutic strategy in oncology.
Purpose of the Study:
- To synthesize and screen a library of novel farnesyl analog compounds.
- To assess the anticancer activity of these compounds in lung and breast cancer cell lines.
- To determine the congruence between designed compound pharmacology and observed effects.
Main Methods:
- Development of a compound library focused on inhibiting KRAS prenyl modification.
- Screening of 67 novel farnesyl analogs for anticancer activity.
- Evaluation of compound effects on MAP kinase phosphorylation as a KRAS inhibition indicator.
Main Results:
- 70% of the novel compounds exhibited activity in at least one tested cancer cell line.
- Two compounds demonstrated inhibition of MAP kinase phosphorylation, suggesting KRAS pathway interference.
- While 47 compounds showed activity, none achieved high potency in initial screening.
Conclusions:
- Inhibiting KRAS prenylation via farnesyl or geranylgeranyl modification is a viable anticancer strategy.
- The developed compounds, though not highly potent, validate the therapeutic approach.
- Further optimization and development of second-generation molecules are ongoing to enhance potency and efficacy.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
02:34Inhibition of Cdk Activity
01:22Antiviral Nucleoside Inhibitors
01:25Mutagenicity and Carcinogenicity
01:28Inhibitors of Bacterial DNA Synthesis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...